Investigational PDTs in Schizophrenia

Patients participating in clinical trials for CT-155 have provided valuable insights into the potential benefits of prescription digital therapeutics (PDTs) for negative symptoms of schizophrenia. This investigational app delivers interactive psychosocial interventions through smartphones over a 16-week period, adapting to individual patient responses to provide personalized therapeutic experiences. Patients can access these interventions at any time of day, providing flexibility and immediate availability that traditional therapy cannot offer.

The CONVOKE clinical trial demonstrated significant benefits for patients using CT-155 compared with those using a control app without therapeutic interventions. Patients in the treatment group showed meaningful improvements in experiential symptoms of schizophrenia while maintaining an excellent safety profile with no significant adverse events. This evidence provides hope for patients who have limited effective treatment options for negative symptoms that significantly impact their daily functioning.

For patients with schizophrenia, particularly younger individuals who are comfortable with technology, CT-155 represents a potentially transformative treatment option. The app’s design recognizes that patients today, especially those diagnosed in their late teens to mid-20s, have grown up with smartphones and are likely to find digital interventions more acceptable than traditional medications with potential adverse effects. Patients deserve access to innovative treatments that leverage familiar technology to address the complex psychological and social challenges of schizophrenia.